OBJECTIVE: Previous in vitro experiments, as well as acute assays in rat showed that the C-terminal domain (CT-domain) of porcine pancreatic lipase behaves as a potent specific noncovalent inhibitor of pancreatic lipase. Nevertheless, the potential use of the CT-domain as a therapeutic tool against obesity in humans requires further investigation and would be best achieved using the human CT-domain. In the present study, we investigated the inhibitory effects of the recombinant human CT-domain, in vivo, upon chronic administration to rats fed a high-fat diet. DESIGN AND MEASUREMENT: The long-term in vivo study requiring relatively high amounts of the human CT-domain, the domain was overexpressed in Escherichia coli as inclusion bodies and an efficient refolding protocol was designed. The inhibitory effect of the recombinant human CT-domain on the activity of pancreatic lipase from different species was first investigated in vitro. Then chronic assays were performed for 4 weeks in rats fed a high-fat diet with or without a daily dose of 1.2 mg of CTdomain per kilogram rat. The time course of food intake, body weight, plasma parameters, liver lipids, faecal output of fat and total cholesterol were measured. RESULTS: A high yield of correctly folded recombinant human CT-domain was obtained using our refolding process, as evidenced by the capability of the recombinant domain to inhibit human horse and porcine pancreatic lipases in vitro. The recombinant human CT-domain had no influence on the food intake, but significantly reduced the body weight gain. As compared to control rats, higher amounts of total fat (mainly triglycerides and monoglycerides) and total cholesterol were found in the faeces of the rats treated with the CT-domain. Finally, a decrease in liver triglycerides and nonesterified cholesterol was observed while no significant effect could be detected on the plasma parameters. CONCLUSIONS: These results demonstrated that the CT-domain efficiently reduces in vivo, lipolysis and subsequently body weight gain in rat fed a high-fat diet. The CT-domain could, therefore, be effective in preventing obesity.
Introduction
Obesity is a severe public health problem in all industrialised countries. Digestion of dietary triglycerides, which represent 90-95% of the total ingested fat, is driven to completion in the intestine by pancreatic lipase, in conjunction with pancreatic colipase and bile. Therefore, in order to reduce dietary fat absorption, strategies aimed to inhibit partially pancreatic lipase were developed to fight obesity. In this respect, a number of studies reported the existence of potential lipase inhibitor in various foodstuffs such as cereals, wheat bran and germ, 1 soybean, 2 medicinal plants, 3 green tea extract 4 or a leguminous plant. 5 Besides these natural products, Orlistat (Ro 18-0647), a derivative of lipstatin from Streptomyces toxitricini, has been shown to reduce by 35% fat absorption in humans. 6 Orlistat inhibits both gastric and pancreatic lipases as well as carboxyl esterase by reacting with the catalytic serine residue of these enzymes. 7 Recently, a novel specific way to inhibit specifically pancreatic lipase was reported. 8 In vitro experiments and acute assays in rat revealed that the CT-domain of pancreatic lipase, which is devoted to colipase binding, behaves as a specific noncovalent inhibitor of the enzyme by diverting part of colipase from its lipase-anchoring function to the bile-coated lipid interface. The inhibitory effect of the CTdomain results from the formation of a nonproductive CTdomain/colipase/micelle ternary complex, 9 which competes for colipase with the active lipase/colipase/micelle ternary complex, thus reducing the amount of active lipase.
These promising results open up new prospects for controlling the dietary triglyceride digestion, but require further investigations. In particular, chronic administration of CT-domain in rats has to be performed to study the longterm effects of this domain on either the digestion or the absorption of dietary fat. In the perspective of a potential therapeutic use of the CT-domain in the health field, this project would be best achieved using the human CT-domain. Obtaining high amounts of the human CT-domain to perform in vivo studies remains a challenge since this could not be achieved neither by limited proteolysis of human pancreatic lipase, 10 nor by expression in insect cells 11 or in yeast.
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In the present study, the inhibitory effect of human CTdomain, produced in E. coli, on lipase activity in vitro and in vivo in rats fed a high-fat diet were investigated.
Materials and methods
Materials pET22b vector, human adult normal pancreas Gene Pool cDNA and E. coli BL21 (DE3) cells were purchased from Invitrogen. Restrictions enzymes were obtained from New England Biolabs (UK). Isopropyl b-d-thiogalactoside, tributyrin and sodium taurodeoxycholate were from Sigma (St Louis, MO, USA).
Preparation of the human CT-domain
Cloning and expression of the human CT-domain in E. coli. The DNA fragment encoding the human lipase CTdomain was amplified by PCR from a human adult normal pancreas Gene Pool cDNA. The cloning was accomplished into the NdeI site located upstream the pelB leader sequence of the pET22b vector using the following 5 0 primer: 5 0 /GGAATTCCATATGGCACGTTGGAGGTATAAGGS3 0 . The built-in NdeI restriction site (in the bold type) also introduced the ATG. The next six codons (in italics) encode the first six N-terminal residues of the human CT-domain. The 3 0 reverse primer, 5 0 /CGGAATTCTTAACACGGTGTGAGGG-TGAGCAGS3 0 , which introduces the EcoRI restriction site (in the bold type), is complementary to the last eight CTresidues of the human CT-domain (in italics). The PCR reaction was carried out under standard conditions with 5 min at 951C as the first step, and then 0.5 min at 951C, 1 min at 501C and 1 min at 721C for 25 cycles. After analysis by electrophoresis on 1% agarose gel, the PCR fragment was purified and sequenced using the dideoxy chain termination method according to Sanger et al. 13 The CT-fragment was then double digested by NdeI and EcoRI and cloned into pET22b vector digested by the same restriction enzymes. The recombinant vector was purified and used to transform E. coli BL21 (DE3) cells. The E. coli BL21 (DE3) harbouring recombinant plasmid were grown on 4 l of LB media 14 containing 100 mg/ml ampicillin at 371C. At an OD 600 nm of 0.3-0.9, isopropyl b-d-thiogalactoside (IPTG) was added to a final concentration of 1 mM and growth was prolonged for 4 h at 371C. Cells were pelleted at 4000 rpm for 10 min.
Refolding and purification of the human recombinant CTdomain. Cells from 4 l cultures were resuspended in a 10 mM Tris/HCl buffer, pH 8.0, containing 23% sucrose and 1.5 mM EDTA (buffer A). Inclusion bodies were isolated by cell disruption using a French press and harvested by centrifugation at 30 000 rpm at 41C for 1 h. The pellet was washed twice with buffer A containing 0.5% Triton X-100, once with buffer A and three times with a 10 mM Tris/HCl buffer, pH 8.0. 15 The inclusion bodies were then dissolved overnight at 41C in a 100 mM Tris/HCl buffer, pH 8.0, containing 6 M guanidinium chloride, at a protein concentration of 8-10 mg/ml. After centrifugation (30 000 rpm, 40 min, 41C), the protein solution was diluted 200 times with buffer B (100 mM Tris/HCl, pH 8.0, 5 mM EDTA, 0.5 M NaCl). After centrifugation (7000 rpm, 30 min, 41C) and dialysis against a 10 mM Tris/HCl buffer, pH 8.0, the CTdomain was purified by chromatography on a hydroxyapatite (BioRad, CA, USA) column equilibrated with the same buffer. The CT-domain was eluted with a four-step (50, 100, 150 and 200 mM) discontinuous potassium phosphate gradient. The fractions containing the CT-domain were pooled, dialysed against distilled water, analysed on 15% SDS-PAGE 16 and freeze-dried.
N-terminal sequence analysis. Stepwise Edman degradation was performed automatically using a gas-phase sequencer (Applied Biosystems, Model 470 A, FL, USA). The resulting phenylthiohydantoins were analysed by HPLC using a C18 column (Brownlee, 5 mm, 220 Â 2.1 mm 2 i.d Applied Biosysteme, FL, USA). They were eluted using a gradient from 10 to 46% methanol in a 7 mM sodium acetate buffer, pH 4.84.
Mass spectrometry. MALDI-MS was performed on a reflection time-of-flight mass spectrometer equipped with delayed extraction (Voyager DE-RP, Perceptive Biosystems Inc., FL. USA). The sample was first dissolved in 10 ml of acetic acid and then diluted with 90 ml of water. From this sample, 0.7 ml (about 4 pmol) was directly mixed on the support with an equal volume of sinapinic matrix (saturated solution of sinapinic acid solution in 40% acetonitrile, 60% water containing 0.1% in trifluoroacteic acid). Analysis was conducted in linear mode using apomyoglobin as calibrant.
In vivo lipolysis inhibition by the lipase CT-domain C Sebban-Kreuzer et al
In vitro inhibitory effect of human CT-domain on lipase activity
Lipase activity was titrimetrically determined at 251C, in the presence of colipase and 4 mM sodium taurodeoxycholate (NaTDC), using 0.11 M emulsified tributyrin in a 1 mM Tris/HCl buffer, pH 7.5, containing 0.1 M NaCl and 5 mM CaCl 2 . The lipase and colipase concentrations were in the order of 10 À9 M. One unit corresponds to the release of 1.0 mmol of fatty acid per min. The lipase activity was measured either in the absence or in the presence of increasing amount of a stock solution of human recombinant CT-domain (10 À4 M).
In vivo effects of the human CT-domain on rats fed a high-fat diet Animals and diet: The study was performed according to the guidelines of the French Department of Agriculture, Fishing and Diet on the experimental use of laboratory animals with agreement no. A 13823. A total of 19 adult male Wistar rats (B350 g) (IFFO-CREDO, l'Arbresle, France), 4-6 weeks old at the beginning of the experiment, were individually housed in wire-bottomed cages and maintained at 221C on a 12 h light-dark cycle. All rats were fed a high-fat diet (Table 1) in which 27% of energy is provided as fat.
Procedures and assays: After 2 days adaptation to the high-fat diet and laboratory conditions, the rats were randomly divided into two groups. One group (n ¼ 9, mean starting weight: 360.877.5 g) was used as control, whereas the second one (n ¼ 10, mean starting weight: 379.876.4 g) was submitted to the diet supplemented with the purified human recombinant CT-domain (1.2 mg/kg rat/day). All rats were allowed water and food ad libitum. Food consumption was measured each day and body weight once a week. Each week, the faeces were collected for four consecutive days, pooled, weighed, diluted in 20 ml water and stored for 24 h at 41C before homogenisation using a polytron. The lipids were extracted according to Folch et al. 17 Faecal triglycerides, diglycerides, monoglycerides, free fatty acids and total cholesterol were separated according to Bitman and Wood 18 and quantified by densitometry after staining with orthophosphoric acid/CuSO 4 (10/8%) for 30 min at 1301C. Blood was taken from caudal puncture 1 day before the beginning of the experiments. Plasma was separated by centrifugation and plasma triglyceride and total cholesterol were determined using Bio-Merieux enzymatic kits. After 4 weeks of human CT-domain treatment, the rats were anaesthetised with ketamine and killed by total exsanguination and blood was taken from abdominal aorta puncture. The blood samples were centrifugated and plasma was kept frozen before analysis. Plasma triglycerides, total cholesterol, glucose, aspartate aminotransferase (AST, E.C. 2.6.1.1) and alanine aminotransferase (ALT, E.C.2.6.1.2) were analysed using commercialised enzymatic kits (Prof. H Portugal, Hôpital Sainte-Marguerite, Marseille, France).
The livers were collected, washed three times with 0.1 M PBS and stored at À201C before analysis. Aliquot (1.5 g) were homogenised in 1 ml of 1 M carbonate/bicarbonate buffer. After filtration of the homogenate, the hepatic lipids were extracted and quantified as above mentioned.
Statistical analyses: The statistical significance of the results was assessed by ANOVA for factorial nonrepeated values and the differences among treatment groups were assessed by Fischer's test. 19 Differences associated with a Pvalue o0.05 were considered statistically significant.
Results
Expression, refolding and purification of human lipase CT-domain The recombinant human CT-domain has been expressed in E. coli at a high level (ca 150 mg/l). The different fractions were analysed by 15% SDS-PAGE, using the porcine CTdomain obtained by limited proteolysis 8 as control (Figure 1 , lane 1). As shown in Figure 1 , the recombinant human CTdomain is mainly produced as inclusion bodies (lane 3). After solubilisation of inclusion bodies, the human CTdomain was refolded as described in Material and methods and purified by chromatography on hydroxyapatite. The purified domain possessed the expected N-terminal sequence Ala-Arg-Trp-Arg-Tyr and a molecular mass of 12794.43 Da as determined by mass spectrometry. Using this protocol, 45 mg of pure refolded human CT-domain were obtained from 1 l of E. coli culture.
In vitro lipase inhibition by the human recombinant CT-domain In order to check the correct folding of the human recombinant CT-domain, the inhibitory effect of the domain towards native lipase was tested using emulsified tributyrin in the presence of 4 mM NaTDC and an equimolar lipase-to- In vivo lipolysis inhibition by the lipase CT-domain C Sebban-Kreuzer et al colipase ratio. These studies were performed using pancreatic lipase and colipase from various species. In all cases, increasing the human CT-domain concentration results in inhibition plots similar to that presented in Figure 2 , from which the plateau and apparent dissociation constant (K i app ) values were calculated ( Table 2 ). The apparent dissociation constant represents the concentration of CT-domain yielding 50% lipase inhibition. An analysis of the plateau and K i app values presented in Table 2 shows that the human recombinant CT-domain displays a similar inhibitory behaviour towards human, horse and porcine pancreatic lipase. Moreover, the inhibitory parameters of the human CTdomain compare well with those previously reported for the native porcine CT-domain. 8 From these results, it can be concluded that the recombinant human domain produced in E. coli adopted a proper conformation using our refolding protocol and that this domain is a general inhibitor of pancreatic lipase.
In vivo inhibition of lipolysis by human CT-domain
Based on these in vitro results, the long-term effects of the human recombinant CT-domain on lipolysis were investigated in rats fed a high-fat diet for 28 days. Feeding a high-fat diet plus CT-domain had no effect on the total caloric intake since the mean food intake per week per rat at 1-4 weeks was not significantly different between the control group (2874.57119.6 kJ/week/rat) and the CTdomain-treated group (2762.4769.4 kJ/week/rat).
The body weight gain was also evaluated every week all along the study. As shown in Figure 3 , although eating as much as the control group, the rats treated with the CTdomain display a lower weight gain than the control rats, the difference between both groups reaching 19% after 4 weeks of treatment. Faecal output of total fat and total cholesterol in faeces was measured each week for four consecutive days. Excretion of total glycerides and total cholesterol into faeces in rats given the CT-domain was significantly larger (2 and 1.7 times, respectively) than in nontreated rats (Figure 4) . Among the glycerides, a significant increase is observed in In vivo lipolysis inhibition by the lipase CT-domain C Sebban-Kreuzer et al triglycerides (3.9 times) and monoglycerides (1.9 times) excretion and to a lesser extent in diglycerides (1.3 times) and free fatty acids (1.4 times) excretion. These findings confirm that the human CT-domain retains its inhibitory effect in vivo and that its efficiency is not altered by a longterm administration.
Comparison of plasma metabolites (triglycerides, phospholipids, total cholesterol, glucose, AST and ALT) in nontreated and CT-domain-treated rats showed no significant differences (Table 3) . High-fat diet induces, in both groups, a significant increase in the plasma total cholesterol whereas no significant change is observed in plasma triglycerides. Contents of total lipid, esterified and nonesterified cholesterol in the liver of both groups of rats at the end of the 4 weeks experimental period are reported in Table 4 . Administration of CT-domain prevented the accumulation of hepatic triglycerides and nonesterified cholesterol.
Discussion
Considering that dietary fat, because of its high caloric value, plays an important role in the development of obesity, reduction of fat digestion through pancreatic lipase inhibition is now considered as a novel approach in obesity treatment. The pancreatic lipase CT-domain offers a new way for inhibiting intestinal lipolysis by competing with pancreatic lipase for colipase. In this respect, the CT-domain is a very specific inhibitor of pancreatic lipase, compared to the leading obesity drug, Orlistat (Ro 18-0647), which inhibits the various lipases of the digestive tract. 20 The aim of this study was to evaluate in vivo the inhibitory effect of the lipase CT-domain on lipolysis during chronic studies on rats fed a high-fat diet. A high amount of the human CT-domain being required to perform this study, the domain was produced in E. coli. An efficient refolding procedure was designed that results in high yields of biologically active human recombinant CT-domain as evidenced by its ability to inhibit, in vitro, the activity of various pancreatic lipases on emulsified tributyrin in the presence of colipase and bile salt micelles. The kinetic parameters of inhibition, in each case, were very close to those previously determined using the porcine CT-domain obtained by proteolysis, 10 thus confirming the well-known conservation of the lipase/colipase binding among species. 21 Based on these in vitro results, the long-term effects of human recombinant CT-domain administration to rats fed a high-fat diet were investigated. A significant inhibition of body weight gain was observed in the CT-domain-treated rats as compared to the nontreated rats. Except for the result obtained at 2 weeks of treatment, which is difficult to interpret, the difference noticeable from the very first week In all cases, the differences between the two groups of rats are significant (Po0.05). FA, fatty acid; MG, monoglycerides; DG, diglycerides; TG, triglycérides; TotalG, total glycerides; TotalC, total cholesterol. Values are the mean7s.e.m. of 10 rats for CT-domain-treated and 9 for nontreated rats. AST, aspartate aminotransferase; ALT, alanine aminotransferase.
a b Indicate significant differences (Po0.05) between J1 and J28. Values are the mean7s.e.m. for n = 10 for CT-domain-treated and n=9 for non-treated rats.
a b Indicate significant differences (Po0.05) between both groups of rats. FA, fatty acid; MG, monoglyceride; DG, diglyceride; TG, triglyc´eride; EC, esterified cholesterol; FC, nonesterified cholesterol.
In vivo lipolysis inhibition by the lipase CT-domain C Sebban-Kreuzer et al becomes statistically significant (19%) after the third week. It is noteworthy that this inhibition did not depend on a decreased food intake since there was no difference in the amount of food consumed between the two groups of rats, both groups slightly increasing their caloric intake throughout the study. Moreover, in contrast to what has been reported for tetrahydrolipstatin-treated rats, 22 no compensatory hyperphagia was observed in the CT-domain-treated rats, thus indicating that long-term ingestion of CT-domain does not modify the availability of triglycerides, at least over a 28-day period.
The balance test between administered fat and fat excreted in faeces revealed a two-fold increase in the latter in the CTdomain-treated rats compared to the control group, thus indicating an inhibition of pancreatic lipase by the CTdomain. This effective inhibition of intestinal lipolysis is very likely to proceed as postulated in vitro, namely the CTdomain acting as a 'protein lure' by binding to rat colipase.
Analysis of the lipid composition showed an increase not only in the excretion of triglycerides, but also in the excretion of the hydrolysis products, notably the monoglycerides. A likely explanation for this observation would be that the presence of the CT-domain, by inducing a transitory inhibition of pancreatic lipase, delays the action of the enzyme in the digestive tract, thus preventing the absorption of the lipolysis products that are released too late in the intestine. The mode of action of the CT-domain is therefore different from that of Orlistat, which covalently inhibits all gastrointestinal lipases 20 and acts in the very first steps of fat digestion. Moreover, these results emphasise the noticeable resistance of the CT-domain to gastric and pancreatic proteolysis, in vivo.
The excretion of total cholesterol is also significantly increased in the CT-domain-treated rats. Since the CTdomain has no influence on the activity of pancreatic cholesterol esterase, and since the lipolysis products facilitate the absorption of cholesterol, reducing lipolysis indirectly lowers the absorption of cholesterol.
Analysis of the plasmatic parameters showed that chronic ingestion of the CT-domain did not induce any marked change in plama triglycerides, cholesterol, phospholipids, glucides, AST and ALT. In the case of AST, the slight decrease observed in the CT-domain-treated rats is indicative of positive effect of the domain on the liver of these animals. Yet, after 28 days of lipid and cholesterol-rich diet, a significant increase of the cholesterolaemia is observed in both groups of rats, emphasising the importance of the diet.
Finally, addition of the CT-domain to a 10% lipid/0.5% cholesterol diet led to a significant decrease of triglyceride and nonesterified cholesterol levels in liver suggesting an amelioration of fatty liver. Moreover, the reduced nonesterified cholesterol level could be of importance since it may induce a subsequent upregulation of hepatic LDL receptors expression which, in turn, will facilitate the clearance of these circulating lipoproteins.
In conclusion, CT-domain is shown to inhibit pancreatic lipase in vivo in rats and to reduce high-fat-diet-induced body weight gain. These data suggest that CT-domain is a strong candidate for an agent that impedes intestinal absorption of dietary fat by inhibiting pancreatic lipase activity.
